这是全人类的福音: 美国的肿瘤研究Loxo公司与制药巨头Bayer公司合作研发的新药Vitrakvi已经得到批量生产许可,
这种药改变了以往针对肿瘤类型，是种针对基因的靶向药物，已经成功在肺癌乳腺癌肠癌甲状腺癌等患者的治疗中得到高达98%的疗效(17%完全治愈，81%肿瘤显著缩小)。
- The FDA on Monday approved a new cancer treatment in an unconventional way: not by tumor type, but rather by the genetic mutation the drug targets.
- The drug, Vitrakvi, was developed by Loxo Oncology in partnership with pharma giant Bayer.
- It's only the second time the FDA has approved a cancer drug's use based on a certain mutation rather than a particular tumor type.
The Food and Drug Administration on Monday took an unconventional approach to approving a new cancer drug.
The drug, Vitrakvi, was developed by Loxo Oncology. It's the company's first drug to get approved.
http://uk.businessinsider.com/fda-approves-loxo-oncologys-larotrectinib-vitrakvi-2018-11?r=US&IR=T
